drugset / Trial / NCT00612001
Vaccine Therapy in Treating Patients With Malignant Glioma
Phase 1
Completed
8 enrolled
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines made from peptides and a person's dendritic cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with malignant glioma.
Timeline
- Start
- 2006-05
- Primary completion
- 2011-01
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine | Vaccine | — | — |